Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging

Annals of Neurology

Volumn 48, Issue 5, 2000, Pages 713-722

  Warach, S ^a,b   Creed Pettigrew, L ^a   Dashe, J F ^a   Pullicino, P ^a   Lefkowitz, David M ^a   Sabounjian, L ^a   Harnett, K ^a   Schwiderski, U ^a   Gammans, R ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITICOLINE;

AGED; ARTICLE; BACKACHE; BRAIN ISCHEMIA; BRAIN PERFUSION; BRAIN PROTECTION; BRAIN SIZE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EDEMA; FEMALE; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0033757829     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(200011)48:5<713::aid-ana4>3.0.co;2-%23     Document Type: Article

References (60)

1. Effects of ischemia and electroconvulsive shock on free fatty acid pool in the brain
2. Brain lipid changes following hypoxia
3. Effect of ischemic anoxia and barbiturate anesthesia on free radical oxidation of mitochondrial phospholipids
4. Radioactivity incorporation into different cerebral phospholipids after oral administration of 14C methyl CDP-choline
5. Enhancement of free fatty acid incorporation into phospholipids by choline plus cytidine
6. Effects of CDP-choline and CDPethanolamine on the alterations in rat brain lipid metabolism induced by global ischemia
7. Effect of cytidine diphosphate choline (CDP-choline) on ischemia-induced alterations of brain lipid in the gerbil
8. Oral cytidine 5'-diphosphate choline administration to rats increases brain phospholipid levels
9. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline
10. Citicoline (CDP-choline): Mechanisms of action and effects in ischemic brain injury
11. The effects of prolonged treatment with citicoline in temporary experimental focal ischemia
12. Citicoline for treatment of experimental focal ischemia: Histologic and behavioral outcome
13. Effects of citicoline combined with thrombolytic therapy in a rat embolic stroke model
14. CDP-choline: Neuroprotection in transient forebrain ischemia of gerbils
15. Synergistic effects of a combination of low-dose basic fibroblast growth factor and citicoline after temporary experimental focal ischemia
16. Results after 90 days of stroke treatment with CDP-choline, concerning a double blind test
17. Therapeutic conduct in light of a cerebral vascular accident and the use of CDP-choline
18. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study
19. CDP choline in cerebral vasculopathy: Clinical evaluation and instrumental semeiology (Italian)
20. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group
21. A randomized efficacy trial of citicoline in patients with acute ischemic stroke
22. Early detection of regional cerebral ischemia in cats: Comparison of diffusion- and T2-weighted MRI and spectroscopy
23. Effect of CP101,606, a novel NR2B subunit antagonist of the N-methyl-D-aspartate receptor, on the volume of ischemic brain damage off cytotoxic brain edema after middle cerebral artery occlusion in the feline brain
24. Reperfusion after thrombolyric therapy of embolic stroke in the rat: Magnetic resonance and biochemical imaging
25. The protective effect of MK-801 on infarct development over a period of 24 h as assessed by diffusion-weighted magnetic resonance imaging
26. Magnetic resonance imaging studies on the effect of the fibrinogen-lowering agent ancrod on cerebral lesions in two rat models of acute stroke
27. Neuroprotective effect of the novel glutamate AMPA receptor antagonist YM872 assessed with in vivo MR imaging of rat MCA occlusion
28. Diffusion-, T2-, and perfusion-weighted nuclear magnetic resonance imaging of middle cerebral artery embolic stroke and recombinant tissue plasminogen activator intervention in the rat
29. The effect of eliprodil on the evolution of a focal cerebral ischaemia in vivo
30. MR evaluation of calcium entry blockers with putative cerebroprotective effects in acute cerebral ischaemia
31. Pharmacologic reversal of acute changes in diffusion-weighted magnetic resonance imaging in focal cerebral ischemia
32. Reversible focal ischemic injury demonstrated by diffusion-weighted magnetic resonance imaging in rats
33. Neuroprotective role of ornithine decarboxylase activation in transient focal cerebral ischaemia: A study using ornithine decarboxylase-overexpressing transgenic rats
34. Diffusion and perfusion magnetic resonance imaging studies to evaluate a noncompetitive N-methyl-D-aspartate antagonist and reperfusion in experimental stroke in rats
35. Glycine site antagonist attenuates infarct size in experimental focal ischemia. Postmortem and diffusion mapping studies
36. Efficacy of intra-arterial and intravenous prourokinase in an embolic stroke model evaluated by diffusion-perfusion magnetic resonance imaging
37. Effect of basic fibroblast growth factor on experimental focal ischemia studied by diffusion-weighted and perfusion imaging
38. A novel endothelin antagonist, A-127722, attenuates ischemic lesion size in rats with temporary middle cerebral artery occlusion: A diffusion and perfusion MRI study
39. Neuronal nitric oxide synthase mutant mice show smaller infarcts and attenuated apparent diffusion coefficient changes in the peri-infarct zone during focal cerebral ischemia
40. Clinical experience with diffusion-weighted MR in patients with acute stroke
41. Fast magnetic resonance diffusion-weighted imaging of acute human stroke
42. Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging
43. Enlargement of human cerebral ischemic lesion volumes measured by diffusion-weighted magnetic resonance imaging
44. Longitudinal magnetic resonance imaging study of perfusion and diffusion in stroke: Evolution of lesion volume and correlation with clinical outcome
45. Diffusion-weighted MR imaging: Diagnostic accuracy in patients imaged within 6 hours of stroke symptom onset
46. Acute and chronic stroke: Navigated spin-echo diffusion-weighted MR imaging
47. Hyperacute stroke: Evaluation with combined multisection diffusion-weighted and hemodynamically weighted echo-planar MR imaging
48. Ischemic lesion volumes in acute stroke by diffusion-weighted magnetic resonance imaging correlate with clinical outcome
49. Prediction of stroke outcome with echoplanar perfusion- and diffusion-weighted MRI
50. Diffusion-weighted magnetic resonance imaging in acute stroke
51. Time course of lesion development in patients with acute stroke: Serial diffusion- and hemodynamic-weighted magnetic resonance imaging
52. Diffusion- and perfusion-weighted MRI. The DWI/PWI mismatch region in acute stroke
53. Acute cerebral ischemia: Evaluation with dynamic contrast-enhanced MR imaging and MR angiography
54. Pathophysiological topography of acute ischemia by combined diffusion-weighted and perfusion MRI
55. The ischemic penumbra: Operationally defined by diffusion and perfusion MRI
56. Reduction of lesion volume in human stroke by citicoline detected by diffusion-weighted magnetic resonance imaging (DWI): A pilot study
57. Correlation of perfusion- and diffusion-weighted MRI with NIHSS score in acute (6.5 hour) ischemic stroke
58. A phantom for diffusion-weighted imaging of acute stroke
59. Citicoline treatment for experimental intracerebral hemorrhage in mice
60. Clinical outcome in ischemic stroke predicted by early diffusion-weighted and perfusion magnetic resonance imaging: A preliminary analysis